Year: 2013
Type: article
Abstract: Currently patients with diabetes comprise up to 25-30% of the census of adult wards and critical care units in our hospitals. Although evidence suggests that avoidance of hyperglycemia (>180 mg/dL) and hypoglycemia (<70 mg/dL) is beneficial for positive outcomes in the hospitalized patient, much of this evidence remains controversial and at times somewhat contradictory. We have recently formed a consortium for Planning Research in Inpatient Diabetes (PRIDE) with the goal of promoting clinical research in the area of management of hyperglycemia and diabetes in the hospital. In this article, we outline eight aspects of inpatient glucose management in which randomized clinical trials are needed. We refer to four as system-based issues and four as patient-based issues. We urge further progress in the science of inpatient diabetes management. We hope this call to action is supported by the American Diabetes Association, The Endocrine Society, the American Association of Clinical Endocrinologists, the American Heart Association, the European Association for the Study of Diabetes, the International Diabetes Federation, and the Society of Hospital Medicine. Appropriate federal research funding in this area will help ensure high-quality investigations, the results of which will advance the field. Future clinical trials will allow practitioners to develop optimal approaches for the management of hyperglycemia in the hospitalized patient and lessen the economic and human burden of poor glycemic control and its associated complications and comorbidities in the inpatient setting.
Source: Diabetes Care
DOI: 10.2337/dc12-2508
Authors: Boris Draznin, Janice Gilden, Sherita H. Golden, Silvio E. Inzucchi, for the PRIDE investigators
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funders: Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Massachusetts General Hospital, Yale University, Gilead Sciences, Vanderbilt University, University of Pennsylvania, Ohio State University, Emory University, University of Missouri, School of Medicine, Boston University, University of Washington, Johns Hopkins University, University of Pittsburgh, Georgetown University, University of Cincinnati, Diabetes Technology Management, Regeneron Pharmaceuticals, Temple University, Rosalind Franklin University of Medicine and Science, Insulet Corporation, MannKind Corporation, Halozyme, Dexcom, Novo Nordisk, Genentech, University of Illinois at Urbana-Champaign, School of Medicine, Vanderbilt University, University of California, Los Angeles, Weill Cornell Medical College, School of Medicine, Emory University, University of California, San Diego, University of California, San Francisco, Walter Reed National Military Medical Center, College of Medicine, University of Cincinnati, National Institute of Diabetes and Digestive and Kidney Diseases, University of Colorado School of Medicine, Anschutz Medical Campus
OpenAlex ID: W2033674753
